Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.

TitlePilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
Publication TypeJournal Article
Year of Publication2014
AuthorsMarks KM, Kitch D, Chung RT, Hadigan C, Andersen J, Tien P, Luetkemeyer A, Alston-Smith B, Glesby MJ
Corporate AuthorsA5239 Team
JournalJ Acquir Immune Defic Syndr
Volume65
Issue3
Pagination345-9
Date Published2014 Mar 1
ISSN1944-7884
KeywordsAdult, Alanine Transaminase, Antiviral Agents, Aspartate Aminotransferases, Female, Genotype, Hepacivirus, Hepatitis C, Chronic, HIV Infections, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Pilot Projects, Retreatment, Ribavirin, RNA, Viral, Thiazolidinediones, Treatment Failure, Treatment Outcome, Viral Load
Abstract

: Insulin resistance is associated with nonresponse to hepatitis C virus (HCV) treatment. In this multicenter, single-arm pilot study, adult, HIV/HCV genotype 1-coinfected previous nonresponders to peginterferon/ribavirin (PegIFN/RBV) with homeostatic model assessment of insulin resistance >2.5 were treated with pioglitazone (PIO) for 24 weeks followed by PegIFN/RBV/PIO. Three of 19 subjects (15.8%) achieved undetectable HCV RNA at week 24 of PegIFN/RBV/PIO, which was not significantly different than the historical null rate of 10% (P = 0.29, lower limit of the exact 1-sided 90% confidence interval 5.9%). Over the 24 weeks of PIO monotherapy, alanine aminotransferase and aspartate aminotransferase declined significantly and correlated with improved metabolic parameters.

DOI10.1097/QAI.0000000000000073
Alternate JournalJ. Acquir. Immune Defic. Syndr.
PubMed ID24525470
PubMed Central IDPMC3998202
Grant List1 UM1 AI068634 / AI / NIAID NIH HHS / United States
5 U01 AI38855 / AI / NIAID NIH HHS / United States
5UO1 AI069502-07 / AI / NIAID NIH HHS / United States
AI 069471 / AI / NIAID NIH HHS / United States
AI69501 / AI / NIAID NIH HHS / United States
DK078772 / DK / NIDDK NIH HHS / United States
IU0IAI69472 / / PHS HHS / United States
K24 AI078884 / AI / NIAID NIH HHS / United States
K24 AI078884 / AI / NIAID NIH HHS / United States
K24 DK078772 / DK / NIDDK NIH HHS / United States
U01 AI069419 / AI / NIAID NIH HHS / United States
U01 AI069471 / AI / NIAID NIH HHS / United States
U01 AI069501 / AI / NIAID NIH HHS / United States
U01 AI069502 / AI / NIAID NIH HHS / United States
U01 AI069502 / AI / NIAID NIH HHS / United States
U01 AI69419 / AI / NIAID NIH HHS / United States
UL1 TR000439 / TR / NCATS NIH HHS / United States
UL1 TR000457 / TR / NCATS NIH HHS / United States
UL1 TR000457 / TR / NCATS NIH HHS / United States
UL1TR000058 / TR / NCATS NIH HHS / United States
UL1TR000439 / TR / NCATS NIH HHS / United States
UM1 AI068634 / AI / NIAID NIH HHS / United States
UM1 AI068636 / AI / NIAID NIH HHS / United States
UM1 AI069412 / AI / NIAID NIH HHS / United States
UM1 AI069419 / AI / NIAID NIH HHS / United States
UM1 AI069496 / AI / NIAID NIH HHS / United States
UM1 AI069501 / AI / NIAID NIH HHS / United States
UM1 AI069503 / AI / NIAID NIH HHS / United States
UM1 AI069511 / AI / NIAID NIH HHS / United States
UM1 AI069511 / AI / NIAID NIH HHS / United States
UM1 AI069532 / AI / NIAID NIH HHS / United States
UM1 AI106701 / AI / NIAID NIH HHS / United States
UM1-AI069503 / AI / NIAID NIH HHS / United States
UM1AI068636 / AI / NIAID NIH HHS / United States
UM1AI069532 / AI / NIAID NIH HHS / United States
/ / Intramural NIH HHS / United States